Literature DB >> 33716495

An update on the role of the microbiome in non-alcoholic fatty liver disease pathogenesis, diagnosis, and treatment.

Marialena Mouzaki1, Rohit Loomba2.   

Abstract

The microbiome was originally postulated to contribute to the pathogenesis of NAFLD when the first studies of dysbiosis in NAFLD were reported. Since then, a number of studies have investigated this finding further, in order to discern whether the dysbiosis is the result of the metabolic dysregulation seen with NAFLD or a contributor to the pathogenesis of this condition.

Entities:  

Keywords:  NASH; bacteria; dysbiosis; ethanol; intestinal barrier

Year:  2020        PMID： 33716495      PMCID： PMC7946055          DOI： 10.1007/s11938-020-00290-2

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN： 1092-8472


  49 in total

1.  Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD.

Authors:  Na Jiao; Susan S Baker; Adrian Chapa-Rodriguez; Wensheng Liu; Colleen A Nugent; Maria Tsompana; Lucy Mastrandrea; Michael J Buck; Robert D Baker; Robert J Genco; Ruixin Zhu; Lixin Zhu
Journal:  Gut       Date:  2017-08-03       Impact factor: 23.059

2.  SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome.

Authors:  Matthew D Hirschey; Tadahiro Shimazu; Enxuan Jing; Carrie A Grueter; Amy M Collins; Bradley Aouizerat; Alena Stančáková; Eric Goetzman; Maggie M Lam; Bjoern Schwer; Robert D Stevens; Michael J Muehlbauer; Sanjay Kakar; Nathan M Bass; Johanna Kuusisto; Markku Laakso; Frederick W Alt; Christopher B Newgard; Robert V Farese; C Ronald Kahn; Eric Verdin
Journal:  Mol Cell       Date:  2011-10-21       Impact factor: 17.970

3.  Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease.

Authors:  Rohit Loomba; Victor Seguritan; Weizhong Li; Tao Long; Niels Klitgord; Archana Bhatt; Parambir Singh Dulai; Cyrielle Caussy; Richele Bettencourt; Sarah K Highlander; Marcus B Jones; Claude B Sirlin; Bernd Schnabl; Lauren Brinkac; Nicholas Schork; Chi-Hua Chen; David A Brenner; William Biggs; Shibu Yooseph; J Craig Venter; Karen E Nelson
Journal:  Cell Metab       Date:  2017-05-02       Impact factor: 27.287

Review 4.  Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.

Authors:  Zobair Younossi; Quentin M Anstee; Milena Marietti; Timothy Hardy; Linda Henry; Mohammed Eslam; Jacob George; Elisabetta Bugianesi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-09-20       Impact factor: 46.802

5.  Trimethylamine N-Oxide Aggravates Liver Steatosis through Modulation of Bile Acid Metabolism and Inhibition of Farnesoid X Receptor Signaling in Nonalcoholic Fatty Liver Disease.

Authors:  Xuying Tan; Yan Liu; Jingan Long; Si Chen; Gongcheng Liao; Shangling Wu; Chunlei Li; Lijun Wang; Wenhua Ling; Huilian Zhu
Journal:  Mol Nutr Food Res       Date:  2019-05-22       Impact factor: 5.914

6.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease.

Authors:  David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal
Journal:  Hepatology       Date:  2005-06       Impact factor: 17.425

7.  Microbiome Signatures Associated With Steatohepatitis and Moderate to Severe Fibrosis in Children With Nonalcoholic Fatty Liver Disease.

Authors:  Jeffrey B Schwimmer; Jethro S Johnson; Jorge E Angeles; Cynthia Behling; Patricia H Belt; Ingrid Borecki; Craig Bross; Janis Durelle; Nidhi P Goyal; Gavin Hamilton; Mary L Holtz; Joel E Lavine; Makedonka Mitreva; Kimberly P Newton; Amy Pan; Pippa M Simpson; Claude B Sirlin; Erica Sodergren; Rahul Tyagi; Katherine P Yates; George M Weinstock; Nita H Salzman
Journal:  Gastroenterology       Date:  2019-06-27       Impact factor: 22.682

8.  Circulating microbiota-derived metabolites: a "liquid biopsy?

Authors:  Gemma Aragonès; Marina Colom-Pellicer; Carmen Aguilar; Esther Guiu-Jurado; Salomé Martínez; Fàtima Sabench; José Antonio Porras; David Riesco; Daniel Del Castillo; Cristóbal Richart; Teresa Auguet
Journal:  Int J Obes (Lond)       Date:  2019-08-06       Impact factor: 5.095

9.  A core gut microbiome in obese and lean twins.

Authors:  Peter J Turnbaugh; Micah Hamady; Tanya Yatsunenko; Brandi L Cantarel; Alexis Duncan; Ruth E Ley; Mitchell L Sogin; William J Jones; Bruce A Roe; Jason P Affourtit; Michael Egholm; Bernard Henrissat; Andrew C Heath; Rob Knight; Jeffrey I Gordon
Journal:  Nature       Date:  2008-11-30       Impact factor: 49.962

Review 10.  Current and future pharmacological therapies for NAFLD/NASH.

Authors:  Yoshio Sumida; Masashi Yoneda
Journal:  J Gastroenterol       Date:  2017-12-16       Impact factor: 7.527
View more
  2 in total

Review 1.  NASH and the Gut Microbiome: Implications for New Therapies.

Authors:  Cynthia J Tsay; Joseph K Lim
Journal:  Clin Liver Dis (Hoboken)       Date:  2022-01-28

Review 2.  Discovery of farnesoid X receptor and its role in bile acid metabolism.

Authors:  John Y L Chiang; Jessica M Ferrell
Journal:  Mol Cell Endocrinol       Date:  2022-03-11       Impact factor: 4.369
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.